Does nebivolol prevent contrast-induced nephropathy in humans?

Clinical Cardiology

Volumn 35, Issue 4, 2012, Pages 250-254

  Günebakmaz, Özgür ^a   Kaya, Mehmet G ^a   Koc, Fatih ^b   Akpek, Mahmut ^a   Kasapkara, Ahmet ^a   Inanc, M Tugrul ^a   Yarlioglues, Mikail ^a   Calapkorur, Bekir ^a   Karadag, Zakir ^a   Oguzhan, Abdurrahman ^a  

^a ERCIYES UNIVERSITY   (Turkey)

^b GAZIOSMANPASA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CREATININE; IOPROMIDE; NEBIVOLOL; SODIUM CHLORIDE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EXPOSURE; EXPERIMENTAL STUDY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICULOGRAPHY; HUMAN; HYDRATION; MAJOR CLINICAL STUDY; MALE; RENAL PROTECTION;

ACETYLCYSTEINE; ADRENERGIC BETA-ANTAGONISTS; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; CREATININE; ETHANOLAMINES; FEMALE; FREE RADICAL SCAVENGERS; HEALTH STATUS INDICATORS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PREOPERATIVE CARE; RISK ASSESSMENT; STATISTICS AS TOPIC; VASOCONSTRICTION;

EID: 84859775816     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.21013     Document Type: Article

References (29)

1. McCullough PA, Adam A, Becker CR, et al. CIN Consensus Working Panel. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006; 98: 5-13.
2. Gruberg L, Mintz GS, Mehran R., The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with preexistent chronic renal insufficiency. J Am Coll Cardiol. 2000; 36: 1542-1548.
3. Levy EM, Viscoli CM, Horwitz RI., The effect of acute renal failure on mortality: a cohort analysis. JAMA. 1996; 275: 1489-1494.
4. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008; 101: 279-285.
5. Toprak O, Cirit M, Tanrisev M, et al. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant. 2008;23:853-859.
6. Folland ED, Parisi EF, Moynihan PF, et al. Assessment of left ventricular ejection fractions by real-time, two-dimensional echocardiography: a comparison of cineangiographic and radionuclide techniques. Circulation. 1979; 60: 760-766.
7. Cockcroft DW, Gault MH., Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
8. Mehran R, Aymong E, Nikolsky E, et al. A simple risk score for prediction of contrast induced nephropathy after coronary intervention. J Am Coll Cardiol. 2004; 44: 393-399.
9. Nash K, Hafeez A, Hou S., Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002; 39: 930-936.
10. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997; 103: 368-375.
11. Kamdar A, Weidmann P, Makoff DL, et al. Acute renal failure following intravenous use of radiographic contrast dyes in patients with diabetes mellitus. Diabetes. 1977; 26: 643-649.
12. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004; 93: 1515-1519.
13. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004; 44: 1780-1785.
14. Lindsay J, Apple S, Pinnow EE, et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv. 2003; 59: 338-343.
15. Klause N, Arendt T, Lins M, et al. Hypoxic renal tissue damage by endothelin-mediated arterial vasoconstriction during radioangiography in man. Adv Exp Med Biol. 1998; 454: 225-234.
16. Arakawa K, Suzuki H, Naitoh M, et al. Role of adenosine in the renal responses to contrast medium. Kidney Int. 1996; 49: 1199-1206.
17. Agmon Y, Peleg H, Greenfeld Z, et al. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest. 1994; 94: 1069-1075.
18. Ribeiro L, de Assuno e Silva F, Kurihara RS, et al. Evaluation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents. Kidney Int. 2004; 65: 589-596.
19. Sandhu C, Newman DJ, Morgan R, et al. The role of oxygen free radicals in contrast induced nephrotoxicity. Acad Radiol. 2002; 9: 436-437.
20. Goldenberg I, Matetzky S., Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies [published correction appears in CMAJ. 2005;173:1210]. CMAJ. 2005; 172: 1461-1471.
21. Masuda M, Yamada T, Mine T, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol. 2007; 100: 781-786.
22. Khoury Z, Schlicht JR, Como J, et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy. 1995; 15: 59-65.
23. Madsen JK, Jensen JW, Sandermann J, et al. Effect of nitrendipine on renal function and on hormonal parameters after intravascular iopromide. Acta Radiol. 1998; 39: 375-380.
24. Lameire NH., Contrast-induced nephropathy-prevention and risk reduction. Nephrol Dial Transplant. 2006; 21:i11-i23.
25. Hoffmann U, Fischereder M, Krüger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004; 15: 407-410.
26. Oldemeyer JB, Biddle WP, Wurdeman RL, et al. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003; 146:E23.
27. Carbonell N, Blasco M, Sanjuán R, et al. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. Int J Cardiol. 2007; 115: 57-62.
28. Weiss R., Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag. 2006; 2: 303-308.
29. Münzel T, Gori T., Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009; 54: 1491-1499.